| For: | Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR, Moreira PI, Duarte AI. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes 2015; 6(6): 807-827 [PMID: 26131323 DOI: 10.4239/wjd.v6.i6.807] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v6/i6/807.htm |
| Number | Citing Articles |
| 1 |
Joana M. Gaspar, Filipa I. Baptista, M. Paula Macedo, António F. Ambrósio. Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline. ACS Chemical Neuroscience 2016; 7(2) doi: 10.1021/acschemneuro.5b00240
|
| 2 |
Ngom Issa Isaac, Decloquement Philippe, Armstrong Nicholas, Didier Raoult, Chabrière Eric. Metaproteomics of the human gut microbiota: Challenges and contributions to other OMICS. Clinical Mass Spectrometry 2019; 14 doi: 10.1016/j.clinms.2019.06.001
|
| 3 |
R. U. Ostrovskaya, T. A. Antipova, S. V. Nikolaev, S. V. Kruglov, I. V. Ozerova, T. A. Gudasheva, S. B. Seredenin. Deficit of Neurotrophins in Experimental Diabetes – Correction with a Proline-Containing Dipeptide. Neuroscience and Behavioral Physiology 2019; 49(7) doi: 10.1007/s11055-019-00806-z
|
| 4 |
Yingna Mei, Yubing Li, Yanxiang Cheng, Ling Gao. The effect of gastric bypass surgery on cognitive function of Alzheimer's disease and the role of GLP1-SGLT1 pathway. Experimental Neurology 2023; 363 doi: 10.1016/j.expneurol.2023.114377
|
| 5 |
Brian DellaValle, Gitte S. Brix, Birgitte Brock, Michael Gejl, Anne M. Landau, Arne Møller, Jørgen Rungby, Agnete Larsen. Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats. Frontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00433
|
| 6 |
Y. H. Lee-Barkey, B. Stratmann, D. Tschöpe. Inkretinbasierte Diabetesmedikamente. Der Diabetologe 2017; 13(7) doi: 10.1007/s11428-017-0269-8
|
| 7 |
Lei Meng, Zhe Wang, Hong-Fang Ji, Liang Shen. Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's disease. Cell & Bioscience 2022; 12(1) doi: 10.1186/s13578-022-00768-9
|
| 8 |
Alireza Mohammad Karim. Principles and Biomedical Applications of Self-Assembled Peptides: Potential Treatment of Type 2 Diabetes Mellitus. Pharmaceutics 2024; 16(11) doi: 10.3390/pharmaceutics16111442
|
| 9 |
Julien Ognard, Sevda Alipour Khabir, Sherief Ghozy, Gerard El Hajj, Kevin M. Kallmes, John J. Chen, Ramanathan Kadirvel, David F. Kallmes, Waleed Brinjikji. Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review. The Journal of Headache and Pain 2025; 26(1) doi: 10.1186/s10194-025-02148-3
|
| 10 |
Qian Shi, Shuqian Liu, Vivian A Fonseca, Tina K Thethi, Lizheng Shi. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open 2019; 9(7) doi: 10.1136/bmjopen-2018-024954
|
| 11 |
Grazyna Lietzau, Thomas Nyström, Claes-Göran Östenson, Vladimer Darsalia, Cesare Patrone. Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. Oncotarget 2016; 7(5) doi: 10.18632/oncotarget.6823
|
| 12 |
Jiaxin Yu, Guoxing Chen, Yan Jin, Min Zhang, Tao Wu. Research Progress of Bioactive Peptides in Improving Type II Diabetes. Foods 2025; 14(3) doi: 10.3390/foods14030340
|
| 13 |
A Young Sim, Sumit Barua, Jong Youl Kim, Yong-ho Lee, Jong Eun Lee. Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. Frontiers in Neuroscience 2021; 15 doi: 10.3389/fnins.2021.708547
|
| 14 |
Yan Zhang, Yang Liu, V. Wee Yong, Mengzhou Xue. Omarigliptin inhibits brain cell ferroptosis after intracerebral hemorrhage. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-41635-y
|
| 15 |
. 2018; doi: 10.70675/fdca5023zf0e0z4e14za647z153137b2be38
|
| 16 |
Mette N. Jensen, Ida M. E. Israelsen, Jonathan H. Wardman, Dennis B. Jensen, Daniel B. Andersen, Trine L. Toft-Bertelsen, Martin F. Rath, Jens Juul Holst, Mette M. Rosenkilde, Nanna MacAulay. Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats. Fluids and Barriers of the CNS 2025; 22(1) doi: 10.1186/s12987-025-00652-x
|
| 17 |
Ao Shang, Jiangang Shen. Gut microbiota and their metabolites in stroke: From mechanistic study toward therapeutic perspectives. Pharmacological Research 2026; 225 doi: 10.1016/j.phrs.2026.108147
|
| 18 |
Yunfang Su, Ningning Liu, Zijuan Zhang, Hao Li, Jinlian Ma, Ye Yuan, Ming Shi, Jihong Liu, Zhenrong Zhao, Zhenqiang Zhang, Christian Holscher. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models. European Journal of Pharmacology 2022; 926 doi: 10.1016/j.ejphar.2022.175029
|
| 19 |
Vandana Blossom, Sheetal D. Ullal, Rajalakshmi Rai, Melisha Michael D souza, P. Gopal Govind Kalluraya, Ayush Dixit, P. J. Jiji, B. V. Murlimanju. Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review. 3 Biotech 2025; 15(9) doi: 10.1007/s13205-025-04455-7
|
| 20 |
Yang Gou, Michael W. Schwartz. How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?. Journal of Clinical Investigation 2023; 133(19) doi: 10.1172/JCI174597
|
| 21 |
Ahmed M. Kabel, Mohamed S. Omar, A. Alhadhrami, Salman S. Alharthi, Majed M. Alrobaian. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1. Physiology & Behavior 2018; 188 doi: 10.1016/j.physbeh.2018.01.028
|
| 22 |
Rita Citraro, Michelangelo Iannone, Antonio Leo, Carmen De Caro, Valentina Nesci, Martina Tallarico, Karim Abdalla, Ernesto Palma, Franco Arturi, Giovambattista De Sarro, Andrew Constanti, Emilio Russo. Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis. Brain Research Bulletin 2019; 153 doi: 10.1016/j.brainresbull.2019.08.001
|
| 23 |
Young-Kook Kim, Oh Yoen Kim, Juhyun Song. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.01270
|
| 24 |
Amanda Costa Rodrigues, Adriel Parahyba Lacerda, Lincoln Takashi Hota Mukoyama, Gleyce Barrios de Carvalho, Júlia Aparecida Lima da Mata, Danieli Fernanda Buccini, Octavio Luiz Franco, Ludovico Migliolo. Zebrafish as a translational model for peptide-mediated synaptic dysfunction related to obesity. Frontiers in Synaptic Neuroscience 2026; 18 doi: 10.3389/fnsyn.2026.1845252
|
| 25 |
Qiu-Ju Wang, Yi-Zhe Cui, Xiu-Ying Zhang, Jing Su. Effect of early weaning on the expression of excitatory amino acid transporter 1 in the jejunum and ileum of piglets. Molecular Medicine Reports 2017; 16(5) doi: 10.3892/mmr.2017.7421
|
| 26 |
Christian Hölscher. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs 2020; 29(4) doi: 10.1080/13543784.2020.1738383
|
| 27 |
Hava AÇAR KAYA, Mehmet Aydın AKALAN, İsmail TÜRKMENOĞLU. Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo Model. Kocatepe Veterinary Journal 2022; doi: 10.30607/kvj.1103958
|
| 28 |
J. A. Hutchinson, S. Burholt, I. W. Hamley. Peptide hormones and lipopeptides: from self‐assembly to therapeutic applications. Journal of Peptide Science 2017; 23(2) doi: 10.1002/psc.2954
|
| 29 |
Radwa M. Al-sayed, Mai M. Hasan, Samia Hussein, Aya M. Mohammed, Abdallah S. Abdelazem, Eman M. Abdelghany, Yassmen M. El-sayed, Eman Abdel Raouf Mohammed. The Effect of Intermittent Fasting and Vitamin Supplement on Cognitive Functions in Type 2 Diabetes Mellitus. Bratislava Medical Journal 2025; 126(9) doi: 10.1007/s44411-025-00184-8
|
| 30 |
R. Loera‐Valencia, A. Cedazo‐Minguez, P.A. Kenigsberg, G. Page, A.I. Duarte, P. Giusti, M. Zusso, P. Robert, G. B. Frisoni, Annamaria Cattaneo, M. Zille, J. Boltze, N. Cartier, L. Buee, G. Johansson, B. Winblad. Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine 2019; 286(4) doi: 10.1111/joim.12959
|
| 31 |
Morgana Prá, Gabriela Kozuchovski Ferreira, Aline Haas de Mello, Rosiane de Bona Schraiber, Larissa Colonetti Cardoso, Luana da Rosa Souza, Naiana da Rosa, Jucélia Jeremias Fortunato, Gislaine Tezza Rezin. Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats. Biochemistry and Cell Biology 2016; 94(5) doi: 10.1139/bcb-2016-0016
|
| 32 |
Brian DellaValle, Gitte S. Brix, Birgitte Brock, Michael Gejl, Jørgen Rungby, Agnete Larsen. Oral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain Trauma. Frontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00450
|
| 33 |
Cosmin Sonea, Anca-Liliana Opris, Manuel F. Casanova, Ioan Opris, Marian Vladimir Constantinescu. The Physics of the Mind and Brain Disorders. Springer Series in Cognitive and Neural Systems 2017; 11 doi: 10.1007/978-3-319-29674-6_21
|
| 34 |
Vladimer Darsalia, Thomas Klein, Thomas Nyström, Cesare Patrone. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology 2018; 136 doi: 10.1016/j.neuropharm.2017.08.022
|
| 35 |
Marcio C. Mancini, Maria Edna de Melo. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetology & Metabolic Syndrome 2017; 9(1) doi: 10.1186/s13098-017-0242-0
|
| 36 |
Ivan N. Tyurenkov, Denis V. Kurkin, Dmitry A. Bakulin, Elena V. Volotova, Evgeny I. Morkovin, Mikhail A. Chafeev, Ruben N. Karapetian. Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00543
|
| 37 |
Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho, José Francisco Kerr Saraiva. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovascular Diabetology 2018; 17(1) doi: 10.1186/s12933-018-0800-2
|
| 38 |
|
| 39 |
L. Hao, M. Shi, J. Ma, S. Shao, Y. Yuan, J. Liu, Z. Yu, Zhenqiang Zhang, Christian Hölscher, Zijuan Zhang. A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice. The Journal of Prevention of Alzheimer's Disease 2024; 11(2) doi: 10.14283/jpad.2024.6
|
| 40 |
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, Nigel H. Greig. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research 2022; 186 doi: 10.1016/j.phrs.2022.106550
|
| 41 |
Shuyi Chen, Jie Sun, Gang Zhao, Ai Guo, Yanlin Chen, Rongxia Fu, Yanqiu Deng. Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice. Neurochemical Research 2017; 42(8) doi: 10.1007/s11064-017-2250-8
|
| 42 |
Justin Wan, Caesar Ferrari, Micheal Tadros. GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment. Gastroenterology Insights 2024; 15(1) doi: 10.3390/gastroent15010014
|
| 43 |
Ivan N. Tyurenkov, Alexander A. Ozerov, Denis V. Kurkin, Ekaterina O. Logvinova, Dmitry A. Bakulin, Elena V. Volotova, Dmitry D. Borodin. Structure and biological activity of endogenous and synthetic agonists of GPR119. Russian Chemical Reviews 2018; 87(2) doi: 10.1070/RCR4737
|
| 44 |
Hicham Benabdelkamel, Rajaa Sebaa, Reem H. AlMalki, Afshan Masood, Assim A. Alfadda, Anas M. Abdel Rahman. Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitus. Saudi Pharmaceutical Journal 2024; 32(11) doi: 10.1016/j.jsps.2024.102172
|
| 45 |
Laura Caberlotto, T.-Phuong Nguyen, Mario Lauria, Corrado Priami, Roberto Rimondini, Silvia Maioli, Angel Cedazo-Minguez, Giulia Sita, Fabiana Morroni, Mauro Corsi, Lucia Carboni. Cross-disease analysis of Alzheimer’s disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-39828-5
|
| 46 |
Wenhui Yan, Miao Pang, Ye Yu, Xilan Gou, Peiru Si, Alina Zhawatibai, Yutong Zhang, Meng Zhang, Tingli Guo, Xinyao Yi, Lina Chen. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis. Life Sciences 2019; 231 doi: 10.1016/j.lfs.2019.116566
|
| 47 |
Gang Zhang, Samuel Kim, Xiaohuan Gu, Shan Ping Yu, Ling Wei. DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects. Neuroscience Bulletin 2020; 36(4) doi: 10.1007/s12264-019-00446-w
|
| 48 |
Yvette Ruska, Anett Szilvásy-Szabó, Dóra Kővári, Andrea Kádár, Lilla Mácsai, Richárd Sinkó, Erik Hrabovszky, Balázs Gereben, Csaba Fekete. Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice. Brain Structure and Function 2022; 227(1) doi: 10.1007/s00429-021-02380-y
|
| 49 |
Miaad Bader, Yazhou Li, David Tweedie, Nathan A. Shlobin, Adi Bernstein, Vardit Rubovitch, Luis B. Tovar-y-Romo, Richard D. DiMarchi, Barry J. Hoffer, Nigel H. Greig, Chaim G. Pick. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in Cell and Developmental Biology 2020; 7 doi: 10.3389/fcell.2019.00356
|
| 50 |
Mengjun Zhang, Yubin Wu, Ruonan Gao, Xinwei Chen, Ruiyu Chen, Zhou Chen. Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes. Molecular and Cellular Endocrinology 2022; 542 doi: 10.1016/j.mce.2021.111529
|
| 51 |
Trisha Bhatia, Shweta Sharma. Drug Repurposing: Insights into Current Advances and Future Applications. Current Medicinal Chemistry 2025; 32(3) doi: 10.2174/0109298673266470231023110841
|
| 52 |
Srikanth Jitte, Saritha Keluth, Priya Bisht, Pranay Wal, Sanjiv Singh, Krishna Murti, Nitesh Kumar. Obesity and Depression: Common Link and Possible Targets. CNS & Neurological Disorders - Drug Targets 2024; 23(12) doi: 10.2174/0118715273291985240430074053
|
| 53 |
Emanuel Candeias, Inês Sebastião, Susana Cardoso, Cristina Carvalho, Maria Sancha Santos, Catarina Resende Oliveira, Paula I. Moreira, Ana I. Duarte. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats. Molecular Neurobiology 2017; doi: 10.1007/s12035-017-0622-3
|
| 54 |
Jujun Xue, Cuiqing Wang, Chengli Pan, Haining Xing, Lijuan Xu, Xi Chen, Xuping Wang, Na Wang. Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI. Experimental and Therapeutic Medicine 2019; doi: 10.3892/etm.2019.8339
|
| 55 |
Smita Jain, Ritu Singh, Sarvesh Paliwal, Swapnil Sharma. Targeting Neuroinflammation as Disease Modifying Approach to
Alzheimer’s Disease: Potential and Challenges. Mini-Reviews in Medicinal Chemistry 2023; 23(22) doi: 10.2174/1389557523666230511122435
|
| 56 |
Yun-Han Wang, Kyle Johnson, Sarah Beradid, Hui Yin, Oriana H. Y. Yu, Samy Suissa, Laurent Azoulay, Christel Renoux. Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes. Drug Safety 2026; 49(4) doi: 10.1007/s40264-025-01623-9
|
| 57 |
Shuyi Chen, Mei Zhou, Jie Sun, Ai Guo, Roger Lakmal Fernando, Yanlin Chen, Peng Peng, Gang Zhao, Yanqiu Deng. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling. Neuropharmacology 2019; 157 doi: 10.1016/j.neuropharm.2019.107668
|
| 58 |
. 2019; doi: 10.70675/5cd8042ezb909z42b5z9024z3cb428057fe3
|
| 59 |
Huseyin Emre Arslan, Yasemin Teksen, Orhan Ozatik, Mustafa Cem Algin. The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats. Acta Cirúrgica Brasileira 2025; 40 doi: 10.1590/acb407325
|
| 60 |
Jelena Osmanović Barilar, Ana Babić Perhoč, Ana Knezović, Jan Homolak, Davor Virag, Melita Šalković-Petrišić. The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease. Biomedicines 2023; 11(4) doi: 10.3390/biomedicines11041025
|
| 61 |
Monalisa Rout, Shakti Ketan Prusty, Durga Madhab Kar. Therapies Using Anti-diabetics to Prevent and Manage Progression of Parkinson's Disease. Current Drug Therapy 2025; 20(3) doi: 10.2174/0115748855332557240820054810
|
| 62 |
Ana Knezovic, Jelena Osmanovic Barilar, Ana Babic, Robert Bagaric, Vladimir Farkas, Peter Riederer, Melita Salkovic-Petrisic. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease. Neuropharmacology 2018; 135 doi: 10.1016/j.neuropharm.2018.02.027
|
| 63 |
Christian Hölscher. Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders. British Journal of Pharmacology 2022; 179(4) doi: 10.1111/bph.15508
|
| 64 |
Mohammad Amin Manavi. Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities. Neuropeptides 2022; 94 doi: 10.1016/j.npep.2022.102250
|
| 65 |
In-Kyung Jeong. Extrapancreatic Effect of Glucagon like Peptide-1. The Korean Journal of Medicine 2015; 89(4) doi: 10.3904/kjm.2015.89.4.404
|
| 66 |
Ya-Kun Li, Dong-Xia Ma, Zhi-Min Wang, Xiao-Fan Hu, Shang-Lin Li, Hong-Zhe Tian, Meng-Jun Wang, Yan-Wen Shu, Jun Yang. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis. Pharmacological Research 2018; 131 doi: 10.1016/j.phrs.2018.03.004
|
| 67 |
Shiliang Ji, Xingxing Zhao, Ruifang Zhu, Yongchao Dong, Lifeng Huang, Taiquan Zhang. Metformin and the risk of dementia based on an analysis of 396,332 participants. Therapeutic Advances in Chronic Disease 2022; 13 doi: 10.1177/20406223221109454
|
| 68 |
Brhane Teklebrhan Assefa, Gebrehiwot Gebremedhin Tafere, Dawit Zewdu Wondafrash, Meles Tekie Gidey, Leonel Rojo. The Bewildering Effect of AMPK Activators in Alzheimer’s Disease: Review of the Current Evidence. BioMed Research International 2020; 2020(1) doi: 10.1155/2020/9895121
|
| 69 |
Syed Obaidur Rahman, Madhu Kaundal, Mohd Salman, Apeksha Shrivastava, Suhel Parvez, Bibhu Prasad Panda, Mymoona Akhter, Mohd Akhtar, Abul Kalam Najmi. Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease. European Journal of Pharmacology 2020; 889 doi: 10.1016/j.ejphar.2020.173522
|
| 70 |
Noor Z. Al Dahhan, Elizabeth Cox, Brian J. Nieman, Donald J. Mabbott. Cross-translational models of late-onset cognitive sequelae and their treatment in pediatric brain tumor survivors. Neuron 2022; 110(14) doi: 10.1016/j.neuron.2022.04.009
|
| 71 |
Alla A. Boshchenko, Leonid N. Maslov, Alexander V. Mukhomedzyanov, Olga A. Zhuravleva, Alisa S. Slidnevskaya, Natalia V. Naryzhnaya, Arina S. Zinovieva, Philipp A. Ilinykh. Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists. International Journal of Molecular Sciences 2024; 25(9) doi: 10.3390/ijms25094900
|
| 72 |
Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. International Review of Neurobiology 2020; 155 doi: 10.1016/bs.irn.2020.01.007
|